Myomo, Inc.
Myomo, Inc. (MYO) Stock Overview
Explore Myomo, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
78.3M
P/E Ratio
-15.65
EPS (TTM)
$-0.14
ROE
-0.36%
MYO Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Myomo, Inc. (MYO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 32.15, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1.63.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -15.65 and a market capitalization of 78.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Analyst Recommendations
Price Targets
Company Profile
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Paul R. Gudonis
184
137 Portland Street, Boston, MA
2017